Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults who are 18 years of age or older at the time of giving consent
• People who are willing and able to take part and have signed a written consent form
• People whose case has been reviewed by a specialist team (multidisciplinary board) and who have been found to have not responded to, or are not suitable for, standard treatments
• People who have been diagnosed with primary or secondary liver cancer, confirmed by tissue sample or medical imaging
• People who have at least one liver tumour that can be measured in a specific way using CT or MRI scans
• People whose cancer is mainly affecting the liver (meaning the liver tumours are the main driver of their illness)
• People whose tumours take up less than 50% of the total liver volume, as estimated by the investigating doctor
• People with a life expectancy of at least 3 months from the time of the procedure
• People with a good general level of physical functioning, rated 0 or 1 on a standard medical scale (ECOG score), meaning they are either fully active or able to carry out light activity (confirm with trial site)
• Women who could become pregnant must have a negative pregnancy test before joining
• People who use adequate contraception, where applicable, for both themselves and their partner
• People whose liver is functioning adequately, based on specific blood test results within defined ranges (confirm with trial site for exact values)
• People whose kidneys are functioning adequately, based on specific blood test results within defined ranges (confirm with trial site)
• People whose blood counts are within acceptable ranges, including white blood cells, red blood cells, platelets, and blood clotting measures (confirm with trial site for exact values)
• People whose pre-treatment imaging scan (using a specific radioactive tracer called 99mTc MAA) shows that the substance is reaching the liver tumour as expected
• People who have enough healthy liver tissue remaining outside the area planned for treatment — at least 30% of the total liver volume must be free of tumour and not planned for treatment

Who may not be able to join:

• People with a severe type of blood clot in the main vein supplying the liver (classified as Vp4 under a specific Japanese liver cancer staging system)
• People with a history of serious allergic reactions or intolerances to contrast dyes, sedatives, or certain medications used during procedures, that cannot be managed with other treatments
• People for whom the type of procedure used in this trial (involving a catheter guided into blood vessels near the liver) is medically unsuitable
• People who have previously had external beam radiation therapy directed at the liver
• People who have previously received yttrium-90 microsphere treatment to the liver
• People who have previously received a type of radiation treatment targeting specific receptors (peptide receptor radionuclide therapy / PRRT)
• People who are planning to start a systemic cancer treatment (such as chemotherapy or targeted therapy) within 3 months after the procedure
• People who still have ongoing side effects from a previous treatment that could affect the safety assessment of this trial, as judged by the investigating doctor
• People with evidence of poor lung function or a diagnosed chronic lung condition (such as COPD)
• People who have had a procedure involving a specific part of the digestive tract (the Ampulla of Vater) within the last 3 months, or who have a surgical connection between the bile ducts and the bowel
• People who have fluid build-up in the abdomen (ascites), except for very small trace amounts
• People with moderate to severe confusion or brain function changes related to liver disease (hepatic encephalopathy, Grade 2 or above)
• People who have experienced a serious decline in liver function in the past 6 months, including fluid build-up, confusion, or jaundice
• People whose cancer has a spread-out (infiltrative) pattern that cannot be measured repeatedly on scans
• People who are pregnant or breastfeeding and do not wish to stop
• People with other serious health conditions that would make the trial treatment unsafe, including those currently on dialysis or with unresolved serious infections
• People who are already taking part in another clinical trial involving an intervention
• People whose overall condition leads the investigating doctor to believe they would not be able to safely complete the study
• People who have had a gastrointestinal bleed related to high pressure in the liver's blood vessels within the last 3 months (preventive treatment for this condition is acceptable)
• People whose pre-treatment imaging shows that the radiation dose that would reach the lungs exceeds safe limits
• People whose pre-treatment imaging shows that the radioactive tracer is reaching areas outside the liver that cannot be corrected with additional techniques
• People whose imaging shows poor blood flow to the tumour, meaning the treatment dose would not meet the required levels set out in the trial protocol

Important: Always verify eligibility with the trial site directly before applying.